Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CEST

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09/23 ABBOTT LABORATORIES : and the Fund Provide $2 Million in Additional Relief to He..
09/22 ABBOTT LABORATORIES : Secures FDA Approval for MRI-Compatibility for the Company..
09/22 ABBOTT : Secures FDA Approval for MRI-Compatibility for the Company's Ellipse(TM..
09/22 ABBOTT LABORATORIES PAKISTAN : Dispatch of interim dividend warrants of Abbott L..
09/21 ABBOTT LABORATORIES : Patent Issued for Nutritional Compositions Including Calci..
09/20 ABBOTT : Hosts Conference Call for Third-Quarter Earnings
09/20 ABBOTT LABORATORIES : Lawsuit seeks damages for faulty batteries in St. Jude def..
09/18 ABBOTT LABORATORIES : and the Fund Expand Support for Hurricane Relief with $1 M..
09/15 ABBOTT LABORATORIES : FreeStyle Libre Flash Glucose Monitoring Technology Gains ..
09/14 ABBOTT LABORATORIES : Landmark Study Published in the New England Journal of Med..
More news
News from SeekingAlpha
09/22 FDA OKs MR labeling for Abbott's Ellipse ICD
09/21 Medical Devices Are The Quiet Growth Sector
09/19 MYLAN : Time To Sell?
09/19 I Was Right, There Was An Alpha Opportunity With My 15 Dividend Achievers
09/18 Buy Abbott Laboratories - Cramer's Lightning Round (9/15/17)
Financials ($)
Sales 2017 26 470 M
EBIT 2017 5 762 M
Net income 2017 2 348 M
Debt 2017 14 989 M
Yield 2017 2,04%
P/E ratio 2017 48,25
P/E ratio 2018 27,13
EV / Sales 2017 4,01x
EV / Sales 2018 3,73x
Capitalization 91 233 M
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 54,9 $
Spread / Average Target 4,6%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES33.90%91 233
JOHNSON & JOHNSON14.36%352 651
NOVARTIS12.62%224 990
ROCHE HOLDING LTD.6.62%220 358
PFIZER10.75%214 146
MERCK AND COMPANY11.43%177 633